---
layout: post
title: "Interstitial Cystitis/Bladder Pain Syndrome: Establishing Drug Development Programs for Treatment; Revised Draft Guidance for Industry; Availability"
date: 2026-02-05 18:55:45 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2023-11899
original_published: 2023-06-05 00:00:00 +0000
significance: 8.00
---

# Interstitial Cystitis/Bladder Pain Syndrome: Establishing Drug Development Programs for Treatment; Revised Draft Guidance for Industry; Availability

**Published:** February 05, 2026 18:55 UTC
**Source:** Federal Register
**Original Published:** June 05, 2023 00:00 UTC
**Document Number:** 2023-11899

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a revised draft guidance for industry entitled "Interstitial Cystitis/Bladder Pain Syndrome: Establishing Drug Development Programs for Treatment." This draft guidance is intended to revise and replace the current draft guidance for industry entitled "Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS): Establishing Effectiveness of Drugs for Treatment" issued on December 5, 2019. This draft guidance provides recommendations for drug development programs for drugs intended to treat patients with interstitial cystitis/bladder pain syndrome (IC/BPS).

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2023/06/05/2023-11899/interstitial-cystitisbladder-pain-syndrome-establishing-drug-development-programs-for-treatment)
- API: https://www.federalregister.gov/api/v1/documents/2023-11899

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
